IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX: COR) has completed its previously announced registered direct offering of approximately 5.0 million shares of its common stock and warrants to purchase up to approximately 3.3 million shares of its common stock to institutional investors. The transaction resulted in gross proceeds to Cortex of approximately $5.6 million, excluding any future proceeds from the exercise of the warrants issued in the offering.
